PL2253312T3 - Zastosowanie osmolitów uzyskiwanych z bakterii ekstremofilnych do wytwarzania wziewnych środków leczniczych do profilaktyki i leczenia chorób płucnych i sercowo-naczyniowych oraz urządzenie do inhalacji zawierające osmolity jako składnik czynny - Google Patents

Zastosowanie osmolitów uzyskiwanych z bakterii ekstremofilnych do wytwarzania wziewnych środków leczniczych do profilaktyki i leczenia chorób płucnych i sercowo-naczyniowych oraz urządzenie do inhalacji zawierające osmolity jako składnik czynny

Info

Publication number
PL2253312T3
PL2253312T3 PL10008975T PL10008975T PL2253312T3 PL 2253312 T3 PL2253312 T3 PL 2253312T3 PL 10008975 T PL10008975 T PL 10008975T PL 10008975 T PL10008975 T PL 10008975T PL 2253312 T3 PL2253312 T3 PL 2253312T3
Authority
PL
Poland
Prior art keywords
osmolytes
cardiovascular diseases
pulmonary
prophylaxis
preparation
Prior art date
Application number
PL10008975T
Other languages
English (en)
Inventor
Jean Krutmann
Original Assignee
Bitop Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitop Ag filed Critical Bitop Ag
Publication of PL2253312T3 publication Critical patent/PL2253312T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
PL10008975T 2003-07-07 2004-07-02 Zastosowanie osmolitów uzyskiwanych z bakterii ekstremofilnych do wytwarzania wziewnych środków leczniczych do profilaktyki i leczenia chorób płucnych i sercowo-naczyniowych oraz urządzenie do inhalacji zawierające osmolity jako składnik czynny PL2253312T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10330768A DE10330768A1 (de) 2003-07-07 2003-07-07 Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
EP04740552A EP1641442B1 (de) 2003-07-07 2004-07-02 Verwendung von ectoin und/oder hydroxyectoin zur herstellung von inhalierbaren arzneimitteln sowie eine dies enthaltende inhalationsvorrichtung
EP10008975.4A EP2253312B1 (de) 2003-07-07 2004-07-02 Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eine Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung

Publications (1)

Publication Number Publication Date
PL2253312T3 true PL2253312T3 (pl) 2015-10-30

Family

ID=33559970

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04740552T PL1641442T3 (pl) 2003-07-07 2004-07-02 Zastosowanie ektoiny i/lub hydroksyektoiny do wytwarzania preparatów farmaceutycznych do inhalacji oraz zawierające je urządzenie do inhalacji
PL10008975T PL2253312T3 (pl) 2003-07-07 2004-07-02 Zastosowanie osmolitów uzyskiwanych z bakterii ekstremofilnych do wytwarzania wziewnych środków leczniczych do profilaktyki i leczenia chorób płucnych i sercowo-naczyniowych oraz urządzenie do inhalacji zawierające osmolity jako składnik czynny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL04740552T PL1641442T3 (pl) 2003-07-07 2004-07-02 Zastosowanie ektoiny i/lub hydroksyektoiny do wytwarzania preparatów farmaceutycznych do inhalacji oraz zawierające je urządzenie do inhalacji

Country Status (8)

Country Link
US (2) US20060246007A1 (pl)
EP (2) EP1641442B1 (pl)
JP (1) JP2009513509A (pl)
AT (1) ATE481100T1 (pl)
DE (2) DE10330768A1 (pl)
ES (2) ES2353962T3 (pl)
PL (2) PL1641442T3 (pl)
WO (1) WO2005002556A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858519B1 (de) * 2005-03-12 2013-02-20 Bitop Aktiengesellschaft Für Biotechnische Optimierung Ectoin und/oder hydroxyectoin zur prophylaxe und behandlung chronisch entzündlicher darmerkrankungen
DE102007040615A1 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
DE102008006780A1 (de) * 2008-01-30 2009-08-06 Bitop Ag Verwendung von Tetrahydropyrimidinen
DE102008039231A1 (de) 2008-08-22 2010-02-25 Bitop Ag Verwendung von Glucosylglycerol
CN102847161A (zh) * 2011-06-30 2013-01-02 山东弘立医学动物实验研究有限公司 四氢嘧啶及其衍生物在制备药物肺部收促进剂中的应用
DE102011113059A1 (de) 2011-09-09 2013-03-14 Bitop Ag Therapeutische Anwendungen von Ectoin
ES2437690B1 (es) * 2012-07-10 2014-10-24 Chiesi Farmaceutici S.P.A. Formulaciones inhalatorias en forma de soluciones o de polvos secos, para la eliminación de las secreciones mucosas del aparato respiratorio
FR3022458A1 (fr) 2014-06-23 2015-12-25 Univ Bretagne Occidentale Utilisation du mannosylglycerate et ses derives comme agent immunostimulant
DE102014113781A1 (de) 2014-09-23 2016-03-24 Bitop Ag Solut und Solutgemisch sowie eine Zusammensetzung enthaltend mindestens ein Solut zur Verwendung bei der Prävention oder Behandlung von durch Schwebstaub verursachter kosmetischer oder pathologischer Effloreszenzen
DE102015121050A1 (de) * 2015-12-03 2017-06-08 Bitop Ag Kompatibles Solut oder Solutgemisch zur Verwendung bei der Prävention oder Behandlung von Krankheiten mit Barrieredefekten in Epithelgeweben
DE102016104470A1 (de) 2016-03-11 2017-09-14 Bitop Ag Zusammensetzung zur Förderung der Aktivität von Sirtuinen
DE102020112603A1 (de) * 2020-05-10 2021-11-11 Bitop Aktiengesellschaft Kompatible Solute zur Prävention oder Behandlung von SARS-CoV-2-Infektionen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0385433U (pl) * 1989-09-28 1991-08-29
DE4244580A1 (de) 1992-12-31 1994-07-07 Galinski Erwin A Verfahren zur in vivo Gewinnung von Inhaltsstoffen aus Zellen
DE4342560A1 (de) 1993-12-14 1995-06-22 Marbert Gmbh Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601396D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
DE19933461A1 (de) 1998-07-10 2000-01-13 Beiersdorf Ag Verwendung von Ectoinen und UV-Filtern
DE19834816A1 (de) 1998-08-01 2000-02-03 Merck Patent Gmbh Verwendung von Ectoin oder Ectoin-Derivaten in kosmetischen Formulierungen
AU3760300A (en) * 1999-03-19 2000-10-09 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
JP2001190263A (ja) * 1999-10-27 2001-07-17 Norihiro Kurihara タバコ穴あけ具
DE10006578C2 (de) 2000-02-14 2002-10-31 Bitop Ag Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren
DE10014631A1 (de) 2000-03-24 2001-09-27 Merck Patent Gmbh Verwendung von Ectoin oder Ectoin-Derivaten zur Prophylaxe und/oder Behandlung von UV-induzierter Immunsuppression
US20030147937A1 (en) * 2000-04-12 2003-08-07 Thomas Schwarz Use of compatible solutes as substances having free radical scavenging properties
US6716819B2 (en) * 2000-05-19 2004-04-06 University Of Iowa Research Foundation Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections
DE10044985B4 (de) * 2000-09-11 2019-08-14 Merck Patent Gmbh Verwendung von Ectoin oder Ectoin-Derivaten zum Schutz vor Allergenen
DE10047444A1 (de) 2000-09-21 2002-04-11 Bitop Gmbh Verfahren zur Trennung und hochreinen Isolierung von niedermolekularen, strukturell ähnlichen Verbindungen insbesondere von Tetrahydropyrimidinderivaten wie z.B. 1,4,5,6-Tetrahydro-2-methyl-4-pyrimidincarbonsäuren (Ectoine) und deren Spaltprodukte
FR2819411B1 (fr) * 2001-01-18 2003-02-21 Oreal Composition cosmetique irisee et ses utilisations
FR2826011B1 (fr) * 2001-06-14 2004-12-10 Oreal Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique

Also Published As

Publication number Publication date
EP2253312A2 (de) 2010-11-24
US20060246007A1 (en) 2006-11-02
EP2253312A3 (de) 2011-07-13
ATE481100T1 (de) 2010-10-15
ES2542177T3 (es) 2015-07-31
JP2009513509A (ja) 2009-04-02
WO2005002556A1 (de) 2005-01-13
PL1641442T3 (pl) 2011-04-29
DE502004011662D1 (de) 2010-10-28
EP1641442B1 (de) 2010-09-15
EP1641442A1 (de) 2006-04-05
US20110152294A1 (en) 2011-06-23
EP2253312B1 (de) 2015-04-15
DE10330768A1 (de) 2005-02-24
ES2353962T3 (es) 2011-03-08

Similar Documents

Publication Publication Date Title
JP5863641B2 (ja) 濃縮肥満細胞安定化用薬学的調合物
TWI359675B (en) Bronchodilating β-agonist compositions
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
PL2253312T3 (pl) Zastosowanie osmolitów uzyskiwanych z bakterii ekstremofilnych do wytwarzania wziewnych środków leczniczych do profilaktyki i leczenia chorób płucnych i sercowo-naczyniowych oraz urządzenie do inhalacji zawierające osmolity jako składnik czynny
TWI758617B (zh) 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
MA26892A1 (fr) Formulations pharmaceutiques sous forme de comprimes pour inhalateurs a parer
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
CN106535889A (zh) 用于治疗肺疾病的肥大细胞稳定剂
WO2020181138A1 (en) Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions
WO2005041921A3 (en) Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
WO2015014209A1 (zh) 稳定渗透压的丙酮酸药物组成及其在健康人和肺病病人中的排毒作用
JP2005508963A5 (pl)
GB2430623A (en) Medicaments for treating chronic respiratory disease
US11278602B2 (en) Medicine for Covid-19 and treatment
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
NZ535487A (en) Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration
AP2002002624A0 (en) Use of a combination of compounds in a dry powder inhaler.
JP2004529108A5 (pl)
JP2023551989A (ja) 生成物送達デバイス及び方法
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
CN119700755A (zh) 化合物在制备预防和/或治疗高原病的药物中的应用